20170406 Telix Logo.png
First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer
04 oct. 2021 17h34 HE | Telix Pharmaceuticals Limited
MELBOURNE, Australia and LIÈGE, Belgium, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that a first patient has been dosed...
20170406 Telix Logo.png
Telix Establishes Commercial Hub in Geneva, Switzerland
04 oct. 2021 03h17 HE | Telix Pharmaceuticals Limited
MELBOURNE, Australia and GENEVA, Switzerland, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has established a new commercial...
20170406 Telix Logo.png
Second Industry Body Updates Guidance for Use of PSMA PET Imaging
20 sept. 2021 20h31 HE | Telix Pharmaceuticals Limited
MELBOURNE, Australia and INDIANAPOLIS, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) has today welcomed the Society of Nuclear Medicine and...
20170406 Telix Logo.png
NCCN Guidelines Updated to Include PSMA-PET Imaging
13 sept. 2021 20h36 HE | Telix Pharmaceuticals Limited
MELBOURNE, Australia and INDIANAPOLIS, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) has today welcomed the updated National Comprehensive Cancer...
20170406 Telix Logo.png
FDA Approves Phase II Kidney Cancer Therapy Study
13 sept. 2021 18h41 HE | Telix Pharmaceuticals Limited
MELBOURNE, Australia and INDIANAPOLIS, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States Food and Drug...
20170406 Telix Logo.png
Telix and Radius Sign Italian Distribution Agreement for Prostate Cancer Imaging
12 sept. 2021 18h36 HE | Telix Pharmaceuticals Limited
MELBOURNE, Australia and BOLOGNA, Italy, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an exclusive...
20170406 Telix Logo.png
Telix In-Licences Novel Tumour Microenvironment PET Tracer
09 sept. 2021 01h34 HE | Telix Pharmaceuticals Limited
MELBOURNE, Australia and LIÈGE, Belgium, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an exclusive...
20170406 Telix Logo.png
Michael Didocha Joins Telix as Chief Financial Officer, Americas
31 août 2021 07h12 HE | Telix Pharmaceuticals Limited
MELBOURNE, Australia and INDIANAPOLIS, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) is pleased to announce that Michael Didocha has joined the...
20170406 Telix Logo.png
Telix Expands Prostate Cancer Activity with GenesisCare Collaboration
18 août 2021 18h47 HE | Telix Pharmaceuticals Limited
MELBOURNE, Australia, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today releases details of two ancillary studies under the ProstACT program...
20170406 Telix Logo.png
Two New Studies to Explore Telix Assets in Breast Cancer Theranostics
17 août 2021 21h26 HE | Telix Pharmaceuticals Limited
Breast cancer one of several important indication expansion opportunities for the Telix portfolioFirst patient dosed at Emory University (Atlanta, USA) in a Phase I study of TLX591-CDx for the staging...